effectiveness of treatment

Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results

LYMPHOID TUMORS , ,

T.I. Pospelova1, N.V. Skvortsova1, I.N. Nechunaeva2

1 Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091

2 Municipal Hospital No. 2, 21 Polzunova str., Novosibirsk, Russian Federation, 630051

For correspondence: Nataliya Valer’evna Skvortsova, PhD, associate professor, 52 Krasnyi pr-t, Novosibirsk, Russian Federation, 630091; Tel.: +8(383)279-94-06; e-mail: nata_sk78@mail.ru

For citation: Pospelova T.I., Skvortsova N.V., Nechunaeva I.N. Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results. Klin. Onkogematol. 2015;8(3):267–73. (In Russ.)

ABSTRACT

Objective. To evaluate results of the 7-year experience in treatment of multiple myeloma (MM) with proteasome inhibitor (bortezomib) in the Novosibirsk Municipal Hematological Center.

Methods. 199 MM patients treated in the Novosibirsk Municipal Hematological Center over the period from July, 2006, till December, 2014, were enrolled in the study. The median age of patients was 68 years (varied from 36 to 81). 98 patients received bortezomib as the first line therapy and 101 patients as the second line.

Results. The overall response rate of the first line therapy was 78.5 %; at that, 25 % of patients achieved a complete and almost complete remission. The median time to achieve response was 72 days. With the progression or refractory MM, the efficacy of bortezomib as a part of a combined antitumor therapy was 68.3 %. Bortezomib proved to be effective when its administration was resumed by patients who had received bortezomib and other components of the combined regimen previously (overall response: 68.4 %). The median overall survival rate has not been achieved, and 7-year survival rate was 70 %. Adverse events of bortezomib were predictable and manageable; the most relevant of them included gastrointestinal and hematologic disorders, fatigue, and peripheral neuropathy.

Conclusion. Bortezomib is a highly effective drug, which plays an important role in the treatment of MM as the first and subsequent line therapies; its administration results in significant increase in patients’ overall survival.

Keywords: multiple myeloma, effectiveness of treatment, bortezomib, overall survival.

Received: February 16, 2015

Accepted: May 28, 2015

Read in PDF (RUS)pdficon

REFERENCES

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
  2. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. 5th edition. Philadelphia: Lippincott-Raven; 1997.
  3. Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599–605. doi: 10.1200/jco.2009.25.2114.
  4. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456–63. doi: 10.1172/jci61188.
  5. El-Amm J, Tabbara IA. Emerging Therapies in Multiple Myeloma. J Clin Oncol. 2015;38(3):315–21. doi: 10.1097/COC.0b013e3182a4676b.
  6. Kumar SK, Radjkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20. doi: 10.1182/blood-2007-10-116129.
  7. Kumar SK, et al. Survival in Myeloma Is Improving With Novel Agents. Blood (ASH Annual Meeting Abstracts). 2012:3972.
  8. Вотякова О.М. Современная терапия множественной миеломы. Бюллетень сибирской медицины. 2008;3(приложение):33–41.
    [Votyakova OM. Modern therapy for multiple myeloma. Byulleten’ sibirskoi meditsiny. 2008;3(Suppl):33–41. (In Russ)]
  9. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–72. doi: 10.1182/blood-2007-10-078022.
  10. Montagut C, Rovira A, Mellado B, et al. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today (Barc.). 2005;41(5):299–315. doi: 10.1358/dot.2005.41.5.893706.
  11. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–10. doi: 10.1038/nrc780.
  12. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377–80. doi: 10.1182/blood-2002-06-1768.
  13. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Бортезомиб (Велкейд) в комбинации с дексаметазоном в лечении рефрактерных/рецидивирующих форм множественной миеломы у пожилых больных. Онкогематология. 2010;2:40–5.
    [Bessmel’tsev SS, Karyagina EV, Stel’mashenko LV, et al. Bortezomib (Velcade) in combination with dexamethasone in the treatment of refractory/relapsing forms of multiple myeloma in elderly patients. Onkogematologiya. 2010;2:40–5. (In Russ)]
  14. Richardson PG, Barlogie B, Berenson J. еt al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–17. doi: 10.1056/nejmoa030288.
  15. Richardson PG, Britmberg H, Jagannath S, et al. Characterization and reversibility of peripheral neuropaty in patients with advanced multiple myeloma treated with bortezomib. Summit and Crest study group. Hematol J. 2004;5(Suppl):S129.
  16. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma a randomized, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431. doi: 10.1016/s1470-2045(11)70081-x.
  17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115–23. doi: 10.1046/j.1365-2141.1998.00930.x.
  18. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Результаты лечения множественной миеломы препаратом бортезомиб. Онкогематология. 2009;2:35–41.
    [Pospelova TI, Skvortsova NV, Nechunaeva IN. Results of treatment of multiple myeloma with bortezomib. Onkogematologiya. 2009;2:35–41. (In Russ)]
  19. Скворцова Н.В., Поспелова Т.И., Нечунаева И.Н. и др. Эффективность повторной терапии бортезомибом у пациентов с рефрактерными и рецидивирующими формами множественной миеломы. Бюллетень Сибирского отделения Российской академии медицинских наук. 2013;33(1):76–82.
    [Skvortsova NV, Pospelova TI, Nechunaeva IN, et al. Efficacy of repeated treatment with bortezomib in patients with refractory and relapsing forms of multiple myeloma. Byulleten’ Sibirskogo otdeleniya Rossiiskoi akademii meditsinskikh nauk. 2013;33(1):76–82. (In Russ)]
  20. Скворцова Н.В., Мельникова Т.В., Мельниченко Е.В., Мишенин А.В. Эффективность таргетной терапии множественной миеломы с использованием ингибиторов протеасом. Бюллетень Сибирского отделения Российской академии медицинских наук. 2011;31(2):94–100.
    [Skvortsova NV, Mel’nikova TV, Mel’nichenko EV, Mishenin AV. Efficacy of targeted therapy for multiple myeloma using proteasome inhibitors. Byulleten’ Sibirskogo otdeleniya Rossiiskoi akademii meditsinskikh nauk. 2011;31(2):94–100. (In Russ)]
  21. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. и др. Результаты лечения рефрактерных/рецидивирующих форм множественной миеломы. Гематология и трансфузиология. 2012;57(3):21–2.
    [Pospelova TI, Skvortsova NV, Nechunaeva IN, et al. Results of treatment of refractory/relapsing forms of multiple myeloma. Gematologiya i transfuziologiya. 2012;57(3):21–2. (In Russ)]
  22. Mateos M-V, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93(4):560–5. doi: 10.3324/haematol.12106.
  23. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777–84. doi: 10.1182/blood-2005-03-1173.
  24. NCCN GuidelinesTM Version 1. 2011 Multiple myeloma. Available from: www.nccn.org. (accessed 20.06.2015).

Treatment of Advanced Stage Hodgkin’s Lymphoma: Literature Review

REVIEWS , , , ,

AA Leont’eva, EA Demina

N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Anna Aleksandrovna Leont’eva, graduate student, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel.: +7(499)324-90-89; e-mail: aurevoir-nut@yandex.ru

For citation: Leont’eva AA, Demina EA. Treatment of Advanced Stage Hodgkin’s Lymphoma: Literature Review. Clinical oncohematology. 2015;8(3):255–66 (In Russ).

ABSTRACT

Over the past decade, major research centers with large databases in Europe and the USA have conducted a comprehensive analysis of the effectiveness of treatment programs, delayed treatment-related complications and long-term survival of patients with advanced stage Hodgkin’s lymphoma. This analysis allowed us to develop new, more effective programs and introduce them into practical medicine, as well as to start searching for less toxic treatment options. However, in Russian scientific literature, this complex analysis has not been presented. Available publications and scientific investigations cover only some aspects of diagnosis and treatment of Hodgkin’s lymphoma or selectively discuss the problem of complications. The proposed literature review allows the reader to see the changes in the approach to management of advanced-stage Hodgkin’s lymphoma over the last 75 years: from absolutely pessimistic prognosis for the disease to modern high achievements with further improvement of treatment options for this disease.

Keywords: Hodgkin’s lymphoma, advanced stages, treatment, effectiveness of treatment, toxicity.

Received: February 20, 2015

Accepted: May 28, 2015

Read in PDF (RUS)pdficon

REFERENCES

  1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17:68–114. doi: 10.1177/095952873201700106.
  2. Bonadonna G. Historical review of Hodgkin’s disease. Br J Haematol. 2000;110(3):504–11. doi: 10.1046/j.1365-2141.2000.02197.x.
  3. Diehl V, guest ed. Bailliere’s Clinical Haematology. International Practice and Research. Hodgkin’s Disease. London, Philadelphia, Sydney: Bailliere Tindall; 1996.
  4. Переслегин И.А., Филькова Е.М. Лимфогранулематоз. М.: Медицина, 1975.
    [Pereslegin IA, Fil‘kova EM. Limfogranulematoz. (Lymphogranulomatosis.) Moscow: Meditsina Publ.; 1975. (In Russ)]
  5. Sternberg C. Uber eine Eigenartige, unter dem Bilde der Pseudoleukemie verlaufende Tuberkulose des lymphatische Apparates. Zschr F Heilkunde. 1898;19:21–90.
  6. Reed D. On the pathological changes in Hodgkin’s disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Bull. 1902;10:133–96.
  7. Diehl V, ed. 25 Years German Hodgkin Study Group. Medizin & Wissen; 2004.
  8. Hjalgrim H, Askling J, Sorensen P, et al. Risk of Hodgkin’s disease and other cancer after infectious mononucleosis. J Natl Cancer Inst. 2000;92(18):1522–8. doi: 10.1093/jnci/92.18.1522.
  9. Демина Е.А. Современная терапия первичных больных лимфомой Ходжкина: Автореф. дис. ¼ д-ра мед. наук. М., 2006.
    [Demina EA. Sovremennaya terapiya pervichnykh bol’nykh limfomoi Khodzhkina. (Modern management of primary Hodgkin’s lymphoma patients.) [dissertation] Moscow; 2006. (In Russ)]
  10. Lukes RJ, Butler JJ, Hicks ED. Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer. 1966;19(3):317–44. doi: 10.1002/1097-0142(196603)19:3<317::aid-cncr2820190304>3.0.co;2-o.
  11. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: IARC Press; 2008.
  12. Engert A, Horning SJ, eds. Hematologic malignancies: Hodgkin lymphoma. A Comprehensive Update on Diagnostics and Clinics. Berlin, Heidelberg: Springer; 2011. pp. 65–76.
  13. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2011;22(3, прил. 1).
    [Davydov MI, Aksel’ EM. Cancer statistica in Russia and CIS in 2009. Vestnik RONTs im. N.N. Blokhina RAMN. 2011;22(3 Suppl 1). (In Russ)]
  14. Granger W, Whitaker R. Hodgkin’s disease in bone with special reference to periosteal reaction. Br J Radiol. 1967;40(480):939–48. doi: 10.1259/0007-1285-40-480-939.
  15. Bichel J. The alcohol-intolerance syndrome in Hodgkin’s disease. Acta Med Scand. 1959;164(2):105–12. doi: 10.1111/j.0954-6820.1959.tb00168.x.
  16. James AH. Hodgkin’s disease with and without alcohol-induced pain. A clinical and histological comparison. Q J Med. 1960;29:47–66.
  17. Winiwarter A. Du lymphome malin et du lymphosarcome et de leur traitement. Arch F Arch Klin Chir. 1875;18:98–102.
  18. Pussey WA. Cases of sarcoma and of Hodgkin’s disease treated by exposures to X-rays: preliminary report. JAMA. 1902;98:166–9. doi: 10.1001/jama.1902.62480030024001h.
  19. Gilbert R. La roengentherapie de la granulematise maligne. J Radiol Electrol. 1925;9:509–14.
  20. Демина Е.А. Лимфома Ходжкина: от Томаса Ходжкина до наших дней. Клиническая онкогематология. 2008;1(2):114–8.
    [Demina EA. Hodgkin’s lymphoma: from Thomas Hodgkin till present days. Klinicheskaya onkogematologiya. 2008;1(2):114–8. (In Russ)]
  21. Hoppe RT, Hanlon A, Hanks G, et al. Progress in treatment of Hodgkin’s disease in the United States, 1973 versus 1983: the patterns of care study. Cancer. 1994;74(12):3198–203. doi: 10.1002/1097-0142(19941215)74:12<3198::aid-cncr2820741219>3.0.co;2-9.
  22. Hoppe RT. Radiation therapy in the management of Hodgkin’s disease. Semin Oncol. 1990;17(6):704–15.
  23. Peters MV. A study of survivals in Hodgkin’s disease treated radiologically. Am J Roent. 1950;63:299–311.
  24. Kaplan H. The radical radiotherapy of Hodgkin’s disease. Radiology. 1962;78(4):553–61. doi: 10.1148/78.4.553.
  25. Самочатова Е.В., Владимирская Е.Б., Жесткова Н.М. и др. Болезнь Ходжкина у детей. М.: Алтус, 1997.
    [Samochatova EV, Vladimirskaya EB, Zhestkova NM, et al. Bolezn’ Khodzhkina u detei. (Hodgkin’s disease in children.) Moscow: Altus Publ.; 1997. (In Russ)]
  26. Hoppe RT, Mauch PT, Armitage JO, et al. Hodgkin Lymphoma. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2007.
  27. Prosnitz LR, Farber LR, Fisher JJ, et al. Long term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer. 1976;37(6):2826–33. doi: 10.1002/1097-0142(197606)37:6<2826::aid-cncr2820370638>3.0.co;2-f.
  28. Goodman LS, Wintrobe MM, Dameshek W, et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946;132:126–32.
  29. DeVita VT Jr, Carbone PP. Treatment of Hodgkin’s disease. Med Ann Dist Columbia. 1967;36(4):232–4.
  30. DeVita VT, Serpick AA, et al. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881–95. doi: 10.7326/0003-4819-73-6-881.
  31. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986;4:1295–306.
  32. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986;104(6):739–46. doi: 10.7326/0003-4819-104-6-739.
  33. Даценко П.В., Паньшин Г.А., Сотников В.М. и др. Новые программы комбинированного лечения лимфомы Ходжкина. Онкогематология. 2007;4:27–35.
    [Datsenko PV, Pan’shin GA, Sotnikov VM, et al. New programs of combined treatment of Hodgkin’s lymphoma. Onkogematologiya. 2007;4:27–35. (In Russ)]
  34. Goldman AJ, Goldie JH. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–33.
  35. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5(1):27–37.
  36. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84. doi: 10.1056/nejm199211193272102.
  37. Stefan DC, Stones D. How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma. 2009;50(2):196–9. doi: 10.1080/10428190802663205.
  38. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med. 2002;346(18):1417–8. doi: 10.1056/nejm200205023461821.
  39. Mauch PV, Armitage JO, Diehl V, et al. Hodgkin’s disease. Philadelphia: Lippincott Williams & Wilkins; 1999.
  40. Specht L. Prognostic factors in Hodgkin’s disease. Cancer Treat Rev. 1991;18(1):21–53. doi: 10.1016/0305-7372(91)90003-i.
  41. DeVita VT, Hellman S, Rosenberg SA. Cancer. Principles & Practice of Oncology. 4th edition. Philadelphia; 1993;1819–58.
  42. Richardson SE, McNamara C. The management of classical Hodgkin’s lymphoma: past, present, and future. Adv Hematol. 2011;2011:865870. doi: 10.1155/2011/865870.
  43. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–7. doi: 10.1200/jco.20.3.630.
  44. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009;27(32):5390–6. doi: 10.1200/jco.2009.23.3239.
  45. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–95. doi: 10.1056/nejmoa022473.
  46. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54. doi: 10.1200/jco.2008.19.8820.
  47. Ларина Ю.В., Миненко С.В., Биячуев Э.Р. и др. Лечение распространенных форм лимфомы Ходжкина у подростков и молодых взрослых. Проблема эффективности и токсичности. Онкогематология. 2014;1:11–8.
    [Larina YuV, Minenko SV, Biyachuev ER, et al. Treatment of advance stage Hodgkin’s lymphomas in adolescents and young adults. Efficacy and toxicity problem. Onkogematologiya. 2014;1:11–8. (In Russ)]
  48. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–14.
  49. Diehl V. German Hodgkin Study Group. Haematologica. 2007;92(s5):21, abstract I071.
  50. Богатырева Т.И., Столбовой А.В., Копп М.Ю. и др. Лимфома Ходжкина: трудности на пути реализации стандартов лечения и их преодоление. Врач. 2011;12:34–40.
    [Bogatyreva TI, Stolbovoi AV, Kopp MYu, et al. Hodgkin’s lymphoma: difficulties in implementing treatment standards and ways to overcome them. Vrach. 2011;12:34–40. (In Russ)]
  51. Капланов К.Д., Шипаева А.Л., Васильева В.А. и др. Эффективность программ химиотерапии первой линии при различных стадиях лимфомы Ходжкина. Клиническая онкогематология. 2012;5(1):22–9.
    [Kaplanov KD, Shipaeva AL, Vasil’eva VA, et al. Efficacy of first line chemotherapy programs for different stages of Hodgkin’s lymphomas. Klinicheskaya onkogematologiya. 2012;5(1):22–9. (In Russ)]
  52. Borchmann P, Diehl V, Goergen H, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin Lymphoma: final analysis of the German Hodgkin Study Group HD 11 trial. Blood. 2009;114:299–300.
  53. Thomas J, Ferm C, Noordijk E, et al. Results of the EORTC-GELA H9 randomized trials: the H9-F trials (comparing 3 radiation dose levels) and H9-U trials (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Haematologica. 2007;92(s5):27.
  54. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–52. doi: 10.1016/s1470-2045(13)70341-3.
  55. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112(10):3989–94. doi: 10.1182/blood-2008-06-155820.
  56. Chesson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86. doi: 10.1200/jco.2006.09.2403.
  57. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8. doi: 10.1200/jco.2006.08.2305.
  58. Шахтарина С.В., Павлов В.В., Даниленко А.А., Афанасова Н.В. Лечение больных лимфомой Ходжкина с локальными стадиями: опыт медицинского радиологического научного центра. Онкогематология. 2007;4:36–46.
    [Shakhtarina SV, Pavlov VV, Danilenko AA, Afanasova NV. Treatment of patients with local stages Hodgkin’s lymphomas: experience of medical radiological scientific center. Onkogematologiya. 2007;4:36–46. (In Russ)]
  59. Gallamini A, Hutchings M, Rigacci I, et al. Early interim FDG-PET overshadows the prognostic role of IPS in advanced-stage Hodgkin’s lymphoma treated by conventional ABVD therapy. Haematologica. 2007;32(s5): Abstract C022.
  60. Hoppe RT. Hodgkin’s disease: Second cancer after treatment Hodgkin’s disease: Complications of therapy and excess mortality. Ann Oncol. 1997;8(1):115.
  61. Шахтарина С.В., Даниленко А.А., Павлов В.В. Злокачественные новообразования у больных лимфомой Ходжкина после лучевой терапии по радикальной программе и комбинированной химиолучевой терапии. Клиническая онкогематология. 2008;1(3):246–51.
    [Shakhtarina SV, Danilenko AA, Pavlov VV. Malignant neoplasms in Hodgkin’s lymphoma patients after radiation therapy (according to radical program) and combined chemoradiation therapy. Klinicheskaya onkogematologiya. 2008;1(3):246–51. (In Russ)]
  62. Ильин Н.В., Виноградова Ю.Н. Поздние осложнения терапии больных лимфомой Ходжкина. Практическая онкология. 2007;8(2):96–101.
    [Il’in NV, Vinogradova YuN. Delayed treatment complications in Hodgkin’s lymphoma patients. Prakticheskaya onkologiya. 2007;8(2):96–101. (In Russ)]
  63. Поддубная И.В. Неходжкинские лимфомы. В кн.: Клиническая онкогематология. Под ред. М.А. Волковой. М.: Медицина, 2007. C. 724–71.
    [Poddubnaya IV. Non-Hodgkin’s lymphomas. In: Volkova MA, ed. Klinicheskaya onkogematologiya. (Clinical oncohematology.) Moscow: Meditsina Publ.; 2007. pp. 724–71. (In Russ)]
  64. Поддубная И.В. Обоснование лечебной тактики при неходжкинских лимфомах. Современная онкология. 2002;4(1):3–7.
    [Poddubnaya IV. Rationale for therapeutic management of non-Hodgkin’s lymphoma. Sovremennaya onkologiya. 2002;4(1):3–7. (In Russ)]
  65. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Limfomi Trial. J Clin Oncol. 2009;27(5):805–11. doi: 10.1200/jco.2008.17.0910.
  66. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. The Lancet. 2012;379(9828):1791–9. doi: 10.1016/S0140-6736(11)61940-5.
  67. Bovelli D, Plataniotis G, Roila F. Кардиологическая токсичность химиотерапевтических препаратов и заболевания сердца, обусловленные проведением лучевой терапии. В кн.: Минимальные клинические рекомендации Европейского общества медицинской онкологии. М., 2010. C. 423–33.
    [Bovelli D, Plataniotis G, Roila F. Cardiac toxicity of chemotherapeutic agents and radiotherapy-associated heart diseases. In: Minimal’nye klinicheskie rekomendatsii Evropeiskogo obshchestva meditsinskoi onkologii. (European Society for Medical Oncology (ESMO) Minimum Clinical Recommendations.) Moscow; 2010. pp. 423–33. (In Russ)]
  68. Поддубная И.В., Орел Н.Ф. Кардиотоксичность. В кн.: Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчиковой. М.: Практическая медицина, 2011. С. 435–6.
    [Poddubnaya IV, Orel NF. Cardiac toxicity. In: Perevodchikova NI, ed. Rukovodstvo po khimioterapii opukholevykh zabolevanii. (Guidelines for chemotherapy of tumors.) Moscow: Prakticheskaya Meditsina Publ.; 2011. pp. 435–6. (In Russ)]
  69. Емелина Е.И. Состояние сердечно-сосудистой системы у больных лимфопролиферативными заболеваниями, получавших антрациклиновые антибиотики: Дис. ¼ канд. мед. наук. М., 2007. С. 10–36.
    [Emelina EI. Sostoyanie serdechno-sosudistoi sistemy u bol’nykh limfoproliferativnymi zabolevaniyami, poluchavshikh antratsiklinovye antibiotiki. (Condition of the cardiovascular system inpatients with lymphoproliferative disorders treated with anthracycline antibiotics.) [dissertation] Moscow; 2007. pp. 10–36. (In Russ)]
  70. Матяш М.Г., Кравчук Т.Л., Высоцкая В.В. и др. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал. 2008;6(30):66–75.
    [Matyash MG, Kravchuk TL, Vysotskaya VV, et al. Anthracycline-induced cardiac toxicity: mechanisms of development and clinical manifestations. Sibirskii onkologicheskii zhurnal. 2008;6(30):66–75. (In Russ)]
  71. Семенова А.Е. Кардио- и нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика и лечение). Практическая онкология. 2009;10(3):168–76.
    [Semenova AE. Cardiac and neurotoxicity of anti-tumor agents (pathogenesis, clinical presentation, prevention, and treatment). Prakticheskaya onkologiya. 2009;10(3):168–76. (In Russ)]
  72. Brana I, Tabernero J. Cardiotoxicity. Ann Oncol. 2010;21(Suppl 7):173–9. doi: 10.1093/annonc/mdq295.
  73. Гендлин Г.Е., Сторожаков Г.И., Шуйкова К.В. и др. Острые сердечно-сосудистые события во время применения противоопухолевых химиопрепаратов: клинические наблюдения. Клиническая онкогематология. 2011;4(2):155–64.
    [Gendlin GE, Storozhakov GI, Shuikova KV, et al. Acute cardiovascular events during treatment with anti-tumor chemotherapeutic agents: clinical observations. Klinicheskaya onkogematologiya. 2011;4(2):155–64. (In Russ)]
  74. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol. 1992;19(5):529–42.
  75. Gewlling M, Mertens L, Moerman P, et al. Idiopathic restrictive cardiomyopathy in childhood. Eur Heart J. 1996;17(9):1413–20. doi: 10.1093/oxfordjournals.eurheartj.a015076.
  76. Матяш М.Г., Кравчук Т.Л., Высоцкая В.В. и др. Неантрациклиновая кардиотоксичность. Сибирский онкологический журнал. 2009;5(35):73–82.
    [Matyash MG, Kravchuk TL, Vysotskaya VV, et al. Non-anthracycline-related cardiac toxicity. Sibirskii onkologicheskii zhurnal. 2009;5(35):73–82. (In Russ)]
  77. Escoto H, Ringewald J, Kalpatthi R. Etoposide-related cardiotoxicity in a child with haemophagocytic lymphohistiocytosis. J Cardiol Young. 2010;20(1):105–7. doi: 10.1017/s1047951109991272.
  78. Calvo-Romero JM, Fernandez-Soria-Pantoja R, Arrebola-Garcia JD. Ischemic heart disease associated with vincristine and doxorubicin chemotherapy. Ann Pharmacother. 2001;35(11):1403–5. doi: 10.1345/aph.10358.
  79. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):277–82. doi: 10.1093/annonc/mdq200.
  80. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod. 1999;14(7):1903–7. doi: 10.1093/humrep/14.7.1903.
  81. Шахтарина С.В., Даниленко А.А., Щелконогова Л.Н., Павлов В.В. Беременность, роды и состояние здоровья детей, родившихся у женщин с лимфомой Ходжкина после лучевого или комбинированного химиолучевого лечения. Клиническая онкогематология. 2012;5(3):218–24.
    [Shakhtarina SV, Danilenko AA, Shchelkonogova LN, Pavlov VV. Pregnancy, delivery, and health state of children born to women with Hodgkin’s lymphoma after radiation or combined chemoradiation therapy. Klinicheskaya onkogematologiya. 2012;5(3):218–24. (In Russ)]
  82. Familiary G, Caggiani A, Nottola SA, et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin’s disease. Hum Reprod. 1993;8(12):2080–7.
  83. Zhang Y, Xiao Z, Wang Y, et al. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. PLoS One. 2013;8(11):e80444. doi: 10.1371/journal.pone.0080444.
  84. Huser M, Crha I, Ventruba P, et al. Prevention of ovarian function damage by a GnRh analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod. 2008;23(4):863–8. doi: 10.1093/humrep/den005.
  85. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin’s disease. J Clin Oncol. 1997;20(4):354–7. doi: 10.1097/00000421-199708000-00006.
  86. Пивник А.В., Расстригин Н.А., Моисеева Т.Н. и др. Результаты лечения лимфогранулематоза по протоколу МОРР-ABVD в сочетании с лучевой терапией (десятилетнее наблюдение). Терапевтический архив. 2006;8:57–62.
    [Pivnik AV, Rasstrigin NA, Moiseeva TN, et al. Results of treatment of lymphogranulematosis according to the МОРР-ABVD protocol in combination with radiation therapy (10-year follow-up). Terapevticheskii arkhiv. 2006;8:57–62. (In Russ)]
  87. Redman JR, Bajorunas DR, Goldstein MC, et al. Semen cryopreservation and artificial insemination for Hodgkin’s disease. J Clin Oncol. 1987;5(2):233–8.
  88. Винокуров А.А., Варфоломеева С.Р., Тарусин Д.И. Гонадотоксичность терапии лимфомы Ходжкина у подростков и молодых мужчин: актуальность проблемы и пути решения (обзор литературы). Онкогематология. 2011;2:12–8.
    [Vinokurov AA, Varfolomeeva SR, Tarusin DI. Gonadal toxicity of treatment for Hodgkin’s lymphoma in adolescents and young adults: topicality of the problem and ways of its solution (literature review). Onkogematologiya. 2011;2:12–8. (In Russ)]
  89. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin’s lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111(1):71–6. doi: 10.1182/blood-2007-02-073544.
  90. Винокуров А.А., Варфоломеева С.Р., Тарусин Д.И., Моисеева Т.Н. Оценка гонадотоксичности терапии по схеме ВЕАСОРР-14 у молодых мужчин, излеченных от лимфомы Ходжкина. Клиническая онкогематология. 2011;4(3):235–9.
    [Vinokurov AA, Varfolomeeva SR, Tarusin DI, Moiseeva TN. Evaluation of gonadal toxicity of ВЕАСОРР-14 treatment regimen in young males cured from Hodgkin’s lymphoma. Klinicheskaya onkogematologiya. 2011;4(3):235–9. (In Russ)]
  91. Даниленко А.А., Шахтарина С.В., Афанасова Н.В., Павлов В.В. Изменения в легких у больных лимфомой Ходжкина после химиотерапии по схемам СОРР, ABVD, ВЕАСОРР и облучения средостения в суммарной очаговой дозе 20–30 Грей. Клиническая онкогематология. 2010;3(4):354–8.
    [Danilenko AA, Shakhtarina SV, Afanasova NV, Pavlov VV. Changes in lugs of patients with Hodgkin’s lymphoma after chemotherapy according to СОРР, ABVD, ВЕАСОРР and radiation of mediastinum (total focal dose of 20–30 Gray). Klinicheskaya onkogematologiya. 2010;3(4):354–8. (In Russ)]
  92. Даценко П.В. Сбалансированное сочетание лучевого и лекарственного компонентов при комплексном лечении лимфогранулематоза: Автореф. дис. ¼ д-ра мед. наук. М., 2004.
    [Datsenko PV. Sbalansirovannoe sochetanie luchevogo i lekarstvennogo komponentov pri kompleksnom lechenii limfogranulematoza. (Balanced combination of radiation and chemotherapy in complex treatment of lymphogranulematosis.) [dissertation] Moscow; 2004. (In Russ)]
  93. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: Report of an intergroup trial. J Clin Oncol. 2003;21(4):607–14. doi: 10.1200/jco.2003.12.086.
  94. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–95. doi: 10.1056/nejmoa022473.
  95. Onuma T, Holland JF, Hosi S, et al. Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer. 1974;33(5):1230–8. doi: 10.1002/1097-0142(197405)33:5<1230::aid-cncr2820330507>3.0.co;2-c.
  96. Santrach PJ, Askin FB, Wells RJ, et al. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer. 1989;64(4):806–11. doi: 10.1002/1097-0142(19890815)64:4<806::aid-cncr2820640407>3.0.co;2-x.
  97. Holoye PY, Luna MH, Mackay B, et al. Bleomycin hypersensitivity pneumonitis. Ann Intern Med. 1978;88(1):47–9. doi: 10.7326/0003-4819-88-1-47.
  98. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23(30):7614–20. doi: 10.1200/jco.2005.02.7243.
  99. Carlson RW, Sikic BJ. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med. 1983;99(6):823–33. doi: 10.7326/0003-4819-99-6-823.
  100. Samuals MI, Johnson PE, Holoye PY, et al. Large-dose bleomycin therapy and pulmonary toxicity. JAMA. 1976;235(11):1117–20. doi: 10.1001/jama.1976.03260370025026.
  101. Catravas LD, Laza JS, Dobuker KJ, et al. Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am Rev Respir Dis. 1983;128(4):740–6.
  102. Simpson AB, Paul J, Graham J, et al. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95; a review of patients with germ cells tumors. Br J Cancer. 1998;78(8):1061–6. doi: 10.1038/bjc.1998.628.
  103. Lower EE, Strohofer S, Baughman RP. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci. 1988;295(3):193–7. doi: 10.1097/00000441-198803000-00006.
  104. Boll B, Gorgen H, Fuchs M, et al. Feasibility and efficacy of ABVD in elderly Hodgkin lymphoma patients: analysis of two randomized prospective multicenter trials of the German Hodgkin Study Group (HD10 and HD11). Blood (ASH Annual Meeting Abstracts). 2010;116:418.
  105. Proctor SJ, Wilkinson J, Culligan D, et al. Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin lymphoma patients over 60 YS evaluated as part of the SHIELD (Hodgkin Elderly) study. Ann Oncol. 2011;22(4):117–8.
  106. Evens AM, Hong F, Gordon LI, et al. Efficacy and tolerability of ABVD and Stanford V for Elderly Advanced-Stage Hodgkin-Lymphoma (HL): analysis from the Phase III Randomized US Intergroup Trial E2496. Ann Oncol. 2011;22(4):118.
  107. Behringer K, Goergen H, Borchmann P, et al. Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin lymphoma: final results of the GHSG HD13 trial. EHA. 2014: Abstract S1290.
  108. Hirsch A, Vander EN, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol. 1996;14(4):1297–305.
  109. Horning SJ, Adhikary A, Rizk N, et al. Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12(2):297–305.
  110. Kaplan HS. Hodgkin’s Disease. 2nd edition. Cambridge: Harvard University Press; 1980.
  111. Prosnitz LR, Farber LR, Fisher JJ, et al. Long term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer. 1976;37(6):2826–33. doi: 10.1002/1097-0142(197606)37:6<2826::aid-cncr2820370638>3.0.co;2-f.
  112. Mauch PV, Armitage JO, Diehl V, et al, eds. Hodgkin’s disease. Philadelphia; 1999.
  113. Brincker H, Bentzen SM. A re-analysis of available dose-response and time-dose data in Hodgkin’s disease. J Radiother Oncol. 1994;30(3):227–30. doi: 10.1016/0167-8140(94)90462-6.
  114. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease. J Clin Oncol. 1997;15(6):2275–87. doi: 10.1016/s1278-3218(98)89074-4.
  115. Ярмоненко С.П., Вайнсон А.А. Радиобиология человека и животных. М.: Высшая школа, 2004.
    [Yarmonenko SP, Vainson AA. Radiobiologiya cheloveka i zhivotnykh. (Radiobiology of human and animal.) Moscow: Vysshaya shkola Publ.; 2004. (In Russ)]
  116. Jakobsson PA, Littbrand B. Fractionation scheme with low individual tumor doses and high total dose. Actа Radiol Ther Phys Biol. 1973;12(4):337–46. doi: 10.3109/02841867309131099.
  117. Акимов А.А., Ильин Н.В. Некоторые биологические аспекты лимфомы Ходжкина и новые подходы к ее терапии. Вопросы онкологии. 2003;49(1):31–40.
    [Akimov AA, Il’in NV. Some biological aspects of Hodgkin’s lymphoma and new approaches to its treatment. Voprosy onkologii. 2003;49(1):31–40. (In Russ)]
  118. Hall EJ. Clinical response of normal tissues. In: Hall EJ, ed. Radiobiology for the Radiologist. 5th edition. Philadelphia: Lippincott Williams &Wilkins, 2000. pp. 352.
  119. Ильин Н.В., Виноградова Ю.Н., Николаева Е.Н., Смирнова Е.В. Значение мультифракционирования дозы радиации при первичном лучевом лечении больных лимфомой Ходжкина. Онкогематология. 2007;4:47–52.
    [Il’in NV, Vinogradova YuN, Nikolaeva EN, Smirnova EV. Value of multifractionation radiotherapy dose for primary treatment of patients with Hodgkin’s lymphoma. Onkogematologiya. 2007;4:47–52. (In Russ)]
  120. Magagnoli M, Marzo K, Balzarotti M, et al. Dimension of Residual CT Scan Mass in Hodgkin’s Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo +/– Radiotherapy. Blood (ASH Annual Meeting Abstracts). 2011;118:93.
  121. Russo F, Corazzelli G, Frigeri F, et al. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014;166(1):118–29. doi: 10.1111/bjh.12862.
  122. Laskar S, Kumar DP, Khanna N, et al. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible? Leuk Lymphoma. 2014;55(10):2356–61. doi: 10.3109/10428194.2013.871631.
  123. Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292–8. doi: 10.1182/blood-2011-07-368167.
  124. Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012;119(18):4123–8. doi: 10.1182/blood-2012-01-405456.
  125. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. The Lancet. 2012;379(9828):1791–9. doi: 10.1016/s0140-6736(11)61940-5.
  126. Younes A, Connors JM, Park S, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. doi: 10.1016/s1470-2045(13)70501-1.
  127. Demina EA, Tumyan GS, Stroyakovskiy DL. Treatment results of six cycles EACOPP-14 ± RT in advanced stage Hodgkin lymphoma. Multicenters study in Russia. 9th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 12–15, 2013. Haematologica. 2013;98(2): Abstract P013.
  128. Демина Е.А. Дискуссионные вопросы лечения распространенных стадий лимфомы Ходжкина. Материалы XVII Российского онкологического конгресса, Москва, 12–14 ноября 2013 г. Злокачественные опухоли. 2013;2:19–22.
    [Demina EA. Controversial issues of treatment of advanced stage Hodgkin’s lymphoma. (Materials of XVII Russian oncological congress, Moscow, November 12–14, 2013.) Zlokachestvennye opukholi. 2013;2:19–22. (In Russ)]
  129. Younes A, Gopal AK, Smith SE. еt al. Smith еt al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol. 2012;30(18):2183–9. doi: 10.1200/jco.2011.38.0410.
  130. LaCasce A, Bociek RG, Matous J, et al. Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. Blood. 2014;124(21): Abstract 293.
  131. Connors J, Ansell S, Park SI, et al. Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. Blood. 2014;124(21): Abstract 292.
  132. Borchmann P, Eichenauer D, Pluetschow A, et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Blood. 2013;122(21): Abstract 4344.
  133. Armand P, Ansell SM, Lesokhin AM, et al. Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma – Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. Blood. 2014;124(21): Abstract 289.
  134. Moskowitz CH, Ribrag V, Michot J, et al. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study. Blood. 2014;124(21): Abstract 290.
  135. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. Blood. 2014;124(21): Abstract 291.